Christine E. Horak
Yale New Haven Hospital
3 papers in the Anchorcite directory, published between 2013 and 2015, cited 18,276 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Cutaneous Melanoma Detection and Management · 3 papers
- Melanoma and MAPK Pathways · 2 papers
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Vanna Chiarion‐Sileni · 2 papers
- Dirk Schadendorf · 2 papers
- Piotr Lukasz Rutkowski · 2 papers
- Michele Maio · 2 papers
- Paolo A. Ascierto · 2 papers
- Georgina Venetia Long · 2 papers
- Margaret K. Callahan · 2 papers
- Michael Andrew Postow · 2 papers
Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).